Literature DB >> 32350115

Protein kinase Cι promotes UBF1-ECT2 binding on ribosomal DNA to drive rRNA synthesis and transformed growth of non-small-cell lung cancer cells.

Verline Justilien1, Kayla C Lewis2, Kayleah M Meneses2, Lee Jamieson2, Nicole R Murray2, Alan P Fields1.   

Abstract

Epithelial cell-transforming sequence 2 (ECT2) is a guanine nucleotide exchange factor for Rho GTPases that is overexpressed in many cancers and involved in signal transduction pathways that promote cancer cell proliferation, invasion, and tumorigenesis. Recently, we demonstrated that a significant pool of ECT2 localizes to the nucleolus of non-small-cell lung cancer (NSCLC) cells, where it binds the transcription factor upstream binding factor 1 (UBF1) on the promoter regions of ribosomal DNA (rDNA) and activates rDNA transcription, transformed cell growth, and tumor formation. Here, we investigated the mechanism by which ECT2 engages UBF1 on rDNA promoters. Results from ECT2 mutagenesis indicated that the tandem BRCT domain of ECT2 mediates binding to UBF1. Biochemical and MS-based analyses revealed that protein kinase Cι (PKCι) directly phosphorylates UBF1 at Ser-412, thereby generating a phosphopeptide-binding epitope that binds the ECT2 BRCT domain. Lentiviral shRNA knockdown and reconstitution experiments revealed that both a functional ECT2 BRCT domain and the UBF1 Ser-412 phosphorylation site are required for UBF1-mediated ECT2 recruitment to rDNA, elevated rRNA synthesis, and transformed growth. Our findings provide critical molecular insight into ECT2-mediated regulation of rDNA transcription in cancer cells and offer a rationale for therapeutic targeting of UBF1- and ECT2-stimulated rDNA transcription for the management of NSCLC.
© 2020 Justilien et al.

Entities:  

Keywords:  cancer biology; cell proliferation; epithelial cell transforming protein 2 (ECT2); gene regulation; non-small cell lung cancer; protein kinase C ι (PKCι); protein-protein interaction; ribosomal DNA transcription; ribosomal ribonucleic acid (rRNA) (ribosomal RNA); ribosome biogenesis; tumor cell biology; upstream binding factor 1 (UBF1)

Mesh:

Substances:

Year:  2020        PMID: 32350115      PMCID: PMC7294082          DOI: 10.1074/jbc.RA120.013175

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  62 in total

1.  An immediate response of ribosomal transcription to growth factor stimulation in mammals is mediated by ERK phosphorylation of UBF.

Authors:  V Y Stefanovsky; G Pelletier; R Hannan; T Gagnon-Kugler; L I Rothblum; T Moss
Journal:  Mol Cell       Date:  2001-11       Impact factor: 17.970

Review 2.  MYC as a regulator of ribosome biogenesis and protein synthesis.

Authors:  Jan van Riggelen; Alper Yetil; Dean W Felsher
Journal:  Nat Rev Cancer       Date:  2010-04       Impact factor: 60.716

3.  Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity.

Authors:  Roderick P Regala; Capella Weems; Lee Jamieson; John A Copland; E Aubrey Thompson; Alan P Fields
Journal:  J Biol Chem       Date:  2005-07-01       Impact factor: 5.157

4.  The chromosome 3q26 OncCassette: A multigenic driver of human cancer.

Authors:  Alan P Fields; Verline Justilien; Nicole R Murray
Journal:  Adv Biol Regul       Date:  2015-12-23

5.  Activity of RNA polymerase I transcription factor UBF blocked by Rb gene product.

Authors:  A H Cavanaugh; W M Hempel; L J Taylor; V Rogalsky; G Todorov; L I Rothblum
Journal:  Nature       Date:  1995-03-09       Impact factor: 49.962

6.  Ect2-Dependent rRNA Synthesis Is Required for KRAS-TRP53-Driven Lung Adenocarcinoma.

Authors:  Verline Justilien; Syed A Ali; Lee Jamieson; Ning Yin; Adrienne D Cox; Channing J Der; Nicole R Murray; Alan P Fields
Journal:  Cancer Cell       Date:  2017-01-19       Impact factor: 31.743

7.  The BRCT domain is a phospho-protein binding domain.

Authors:  Xiaochun Yu; Claudia Christiano Silva Chini; Miao He; Georges Mer; Junjie Chen
Journal:  Science       Date:  2003-10-24       Impact factor: 47.728

Review 8.  The HMG-box: a versatile protein domain occurring in a wide variety of DNA-binding proteins.

Authors:  M Stros; D Launholt; K D Grasser
Journal:  Cell Mol Life Sci       Date:  2007-10       Impact factor: 9.261

Review 9.  BRCT domains: A little more than kin, and less than kind.

Authors:  Dietlind L Gerloff; Nicholas T Woods; April A Farago; Alvaro N A Monteiro
Journal:  FEBS Lett       Date:  2012-05-11       Impact factor: 4.124

10.  Human ECT2 is an exchange factor for Rho GTPases, phosphorylated in G2/M phases, and involved in cytokinesis.

Authors:  T Tatsumoto; X Xie; R Blumenthal; I Okamoto; T Miki
Journal:  J Cell Biol       Date:  1999-11-29       Impact factor: 10.539

View more
  3 in total

1.  ECT2 promotes malignant phenotypes through the activation of the AKT/mTOR pathway and cisplatin resistance in cervical cancer.

Authors:  Xiaoli Liu; Junhua Zhang; Shuang Ju; Lu Liu; Yu Sun; Lingyu Guo; Qianwei Zhen; Sai Han; Wei Lu; Youzhong Zhang
Journal:  Cancer Gene Ther       Date:  2022-09-02       Impact factor: 5.854

2.  Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth.

Authors:  Danielle R Cook; Melissa Kang; Timothy D Martin; Joseph A Galanko; Gabriela H Loeza; Dimitri G Trembath; Verline Justilien; Karen A Pickering; David F Vincent; Armin Jarosch; Philipp Jurmeister; Andrew M Waters; Priya S Hibshman; Andrew D Campbell; Catriona A Ford; Temitope O Keku; Jen Jen Yeh; Michael S Lee; Adrienne D Cox; Alan P Fields; Robert S Sandler; Owen J Sansom; Christine Sers; Antje Schaefer; Channing J Der
Journal:  Cancer Res       Date:  2021-11-04       Impact factor: 13.312

Review 3.  The homeostatic regulation of ribosome biogenesis.

Authors:  Chunyang Ni; Michael Buszczak
Journal:  Semin Cell Dev Biol       Date:  2022-04-16       Impact factor: 7.499

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.